JAM-A expression positively correlated with tumor grade, being clearly higher in glioblastomas than in grade II/III astrocytomas; furthermore, for glioma patients high JAM-A expression was correlated to a negative prognosis [287]. This evidence concerns the gene F11R and central nervous system cancer.